The Cost Effectiveness of the U.S. Export Enhancement Program Bonus Allocation Mechanism

2004 ◽  
Vol 86 (2) ◽  
pp. 375-388 ◽  
Author(s):  
Humei Wang ◽  
Richard J. Sexton
Keyword(s):  
Cost Effectiveness ◽  
Allocation Mechanism ◽  
The Cost ◽  
Export Enhancement Program ◽  
The U.S

scholarly journals 503. The Misappropriation of COVID-19 Related TV Ad Expenditures

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S317-S317
Author(s):  
Kartavya J Vyas
Keyword(s):  
Cost Effectiveness ◽  
Performance Metrics ◽  
Control Measures ◽  
Mortality Data ◽  
Preventive Interventions ◽  
Social Distancing ◽  
Epidemic Curve ◽  
Incidence And Mortality ◽  
The Cost ◽  
The U.S

Abstract Background With nearly three-fourths of the U.S. population isolated in their homes between early March and the end of May, almost all of whom regularly watch television (TV), it was no surprise that companies began to purchase airtime on major television networks to advertise (ad) their brands and showcase their empathy with the populace. But how would the coronavirus disease 2019 (COVID-19) epidemic curve have changed had these same dollars been allocated to proven preventive interventions? Methods Performance and activity metrics on all COVID-19 related TV ads that have aired in the U.S. between February 26th and June 7th, 2020, were provided by iSpot.tv, Inc., including expenditures. COVID-19 incidence and mortality data were collected from the Centers for Disease Control and Prevention (CDC). Descriptive statistics were performed to calculate total TV ad expenditures and other performance metrics across industry categories. Leveraging a previously published stochastic agent-based model that was used to assess the cost-effectiveness of non-pharmaceutical interventions to control COVID-19, the number of cases that would have been prevented had these same dollars been used for preventive interventions was calculated using cost-effectiveness ratios (CERs), the cost divided by cases prevented. Results A total of 1,513 companies purchased TV airtime during the study period, totaling approximately 1.1 million airings, 215.5 billion impressions, and $2.7 billion in expenditures; most of the expenditures were spent by the restaurant (15.9%), electronics and communications (15.4%), and vehicle (13.7%) industries. The CERs for PPE and social distancing measures were $13,856 and $29,552, respectively; therefore, had all of these TV ad dollars instead been allocated to PPE or social distancing measures, approximately 194,908 and 91,386 cases of COVID-19 may have been prevented by the end of the study period, respectively. Figure 2. COVID-19 cases prevented had TV ad expenditures been reallocated for interventions. Conclusion Americans were inundated with COVID-19 related TV ads during the early months of the pandemic and companies are now showing some signs to relent. In times of disaster, however, it is paramount that the private sector go beyond showcasing their empathy and truly become socially responsible by allocating their funds to proven prevention and control measures. Disclosures All Authors: No reported disclosures

Cost effectiveness of DPYD genotyping to screen for dihydropyrimidine dehydrogenase (DPD) deficiency prior to adjuvant chemotherapy for colon cancer.

2021 ◽  
Vol 39 (3_suppl) ◽  
pp. 55-55
Author(s):  
Gabriel A. Brooks ◽  
Stephanie Tapp ◽  
Allan T. Daly ◽  
Jonathan Busam ◽  
Anna N.A. Tosteson
Keyword(s):  
Colon Cancer ◽  
Cost Effectiveness ◽  
Adjuvant Chemotherapy ◽  
Transition Probabilities ◽  
Dihydropyrimidine Dehydrogenase ◽  
Sensitivity Analyses ◽  
Dpyd Gene ◽  
Cancer Screen ◽  
The Cost ◽  
The U.S

55 Background: Fluoropyrimidine chemotherapy agents, including 5-fluorouracil and capecitabine, are the backbone of adjuvant treatment for colon cancer, and adjuvant chemotherapy substantially reduces recurrence and mortality after surgical resection of stage 3 colon cancer. While fluoropyrimidine chemotherapy is generally safe, the risk of severe, potentially fatal chemotherapy toxicity is substantially increased for the 2-3% of U.S. patients with DPD deficiency caused by pathogenic variants in the DPYD gene. DPYD genotype testing is readily available in the U.S. but has not been widely adopted. We evaluated the cost effectiveness of DPYD genotyping prior to adjuvant chemotherapy for colon cancer in the U.S. Methods: We constructed a Markov model to simulate screening for DPD deficiency with DPYD genotyping (versus no screening) among patients receiving fluoropyrimidine-based adjuvant chemotherapy for stage 3 colon cancer. Screen-positive patients were modeled to receive dose-reduced fluoropyrimidine chemotherapy. Model transition probabilities for treatment-related toxicities were derived from published clinical trial data with annotation of DPYD genotype and chemotherapy dosing strategy. Our analysis is from the healthcare perspective, with a time horizon of five years and an annual discount rate of 3% for future costs and benefits. Direct healthcare costs and health utilities were estimated from published sources and converted to 2020 US dollars, and post-treatment survival was modeled from SEER data. The primary outcome was the incremental cost-effectiveness ratio (ICER), defined as dollars per quality-adjusted life year (QALY). We used a value of $100,000/QALY as the cost-effectiveness threshold. One-way sensitivity analyses were used to examine model uncertainty. Results: Compared with no screening, screening for DPD deficiency with DPYD genotyping increased per-patient costs by $106 and improved quality-adjusted survival by 0.0028 QALYs, leading to an ICER of $37,300/QALY. In one-way sensitivity analyses, the ICER exceeded $100,000/QALY when the carrier frequency of pathogenic DPYD gene variants was less than 1.17%, and when the specificity of DPYD genotyping was less than 98.9%. Cost-effectiveness estimates were not sensitive to the cost of DPYD genotyping, the cost of toxicity-related hospitalizations, or the health utility associated with grade 3-4 toxicity. Conclusions: Among patients receiving adjuvant chemotherapy for stage 3 colon cancer, screening for DPD deficiency with DPYD genotyping is a cost-effective strategy for preventing infrequent but severe, sometimes fatal toxicities of fluoropyrimidine chemotherapy.

scholarly journals Daily Almond Consumption in Cardiovascular Disease Prevention via LDL-C Change in the U.S. Population: a Cost-Effectiveness Analysis

2019 ◽  
Author(s):  
Jifan Wang(New Corresponding Author) ◽  
Michelle A. Lee Bravatti ◽  
Elizabeth J. Johnson ◽  
Gowri Raman(Former Corresponding Author)
Keyword(s):  
Cardiovascular Disease ◽  
Cost Effectiveness ◽  
Willingness To Pay ◽  
Cost Effective ◽  
Dietary Factors ◽  
Sensitivity Analyses ◽  
Healthcare Sector ◽  
Cvd Prevention ◽  
The Cost ◽  
The U.S

Abstract Objectives Heart disease is the leading cause of death in the United States. The U.S. Food and Drug Administration approved the health claim that 1.5 ounces (42.5 grams) of nut intake may reduce the risk of cardiovascular disease (CVD). Previous studies have focused on the cost-effectiveness of other foods or dietary factors on primary CVD prevention, yet not in almond consumption. This study aimed to examine the cost-effectiveness of almond consumption in CVD primary prevention. Perspective & Setting This study assessed the cost-effectiveness of consuming 42.5 grams of almond from the U.S. healthcare sector perspective. Methods A decision model was developed for 42.5 grams of almond per day versus no almond consumption and CVD in the U.S. population. Parameters in the model were derived from the literature, which included the probabilities of increasing LDL-C, developing acute myocardial infarction (MI) and stroke, treating MI, dying from the disease and surgery, as well as the costs of the disease and procedures in the U.S. population, and the quality-adjusted life years (QALY). The cost of almonds was based on the current price in the U.S. market. Sensitivity analyses were conducted for different levels of willingness-to-pay, the probabilistic sensitivity analysis, ten-year risk prevention, different costs of procedures and almond prices, and patients with or without CVD. Results The almond strategy had $363 lower cost and 0.02 higher QALY gain compared to the non-almond strategy in the base-case model. The annual net monetary benefit (NMB) of almond consumption was $1,421 higher per person than no almond consumption, when the willingness to pay threshold was set at $50,000 for annual health care expenditure. Almond was more cost-effective than non-almond in CVD prevention in all the sensitivity analyses. Conclusion Consuming 42.5 grams of almonds per day is a cost-effective approach to prevent CVD in the short term and potentially in the long term.

Cost-effectiveness of tyrosine kinase inhibition in first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e20504-e20504 ◽  
Author(s):  
Jiaqi Han ◽  
Huabin Hu ◽  
Mengting Liao ◽  
Longjiang She ◽  
Linli Yao ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Tyrosine Kinase ◽  
Egfr Mutation ◽  
Cost Effective ◽  
Small Cell ◽  
Sensitivity Analyses ◽  
Small Cell Lung ◽  
First Line ◽  
The Cost ◽  
The U.S

e20504 Background: Patients with advanced non-small cell lung cancer (NSCLC) harbouring an epidermal growth factor receptor (EGFR) mutation have improved survival with tyrosine kinase inhibitor (TKI) treatments, but the economic efficiency of this application is unclear, especially in limited health resource settings. To inform policy makers about the value of these medications, we developed a Markov model to compare the cost-effectiveness of these strategies. Methods: A Markov model was developed to compare the cost-effectiveness of chemotherapy, gefitinib, erlotinib, afatinib and osimertinib treatments from a public payers’ perspective in the U.S and China. Health states consisted of progression-free survival, progressive disease, and death. Model transition, adverse event probabilities, disease progression, and death were obtained from randomized clinical trials and network meta-analysis. Costs, quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs) over a 10-year lifetime horizon were calculated. One-way and probabilistic sensitivity analyses were performed by multiple potentially modifiable parameters. Results: The tyrosine kinase inhibitors were more cost-effective than chemotherapy treatment in both the U.S and China. In the U.S, compared with erlotinib, afatinib had an ICER of $241,420/QALY while osimertinib had an ICER of $351,315/QALY. In China, the incremental utility for osimertinib versus gefitinib was 0.68QALYs, and the ICER was $25,622/QALY. The probability sensitivity analyses also illustrated that the erlotinib was the optimal treatment at a willingness-to-pay (WTP) threshold of $150,000/QALY in the U.S and osimertinib was the most cost-effective treatment at a WTP of $26,508/QALY in China. Conclusions: Based on our current analysis, erlotinib appears to be the preferred first-line treatment for advanced EGFR mutation-positive NSCLC patients in the US at a WTP of $150,000/QALY. However, because of the price reduction and more health benefits, osimertinib was considered to be most cost-effective at a WTP of $26,508/QALY in China.

Abstract 616: The Population Impact and Cost-Effectiveness of Blood Pressure Treatment in U.S. Adults Age 75 and Older

Hypertension ◽  
2013 ◽  
Vol 62 (suppl_1) ◽  
Author(s):  
Michelle C Odden ◽  
Pamela Coxson ◽  
Andrew Moran ◽  
David Guzman ◽  
Lee Goldman ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Cost Effectiveness ◽  
Side Effects ◽  
Systolic Blood Pressure ◽  
Blood Pressure Target ◽  
Blood Pressure Treatment ◽  
Artery Disease ◽  
The Cost ◽  
The Impact ◽  
The U.S

Introduction: In the next 30 years, the population of adults 75 years and older will more than double in the U.S., and high blood pressure is the most prevalent cardiovascular risk factor in this population. The impact of strategies for blood pressure control has not been evaluated in this population with special consideration of geriatric conditions that may alter the cost-effectiveness. Methods: Based on the Cardiovascular Disease Policy Model, a Markov model of the U.S. population, we forecasted the population impact of blood pressure treatment over 10 years in adults aged 75-94 years, using the health care system perspective, and assuming an annual discount rate of 3%. Based on epidemiologic and trial data, we projected the impact of four potential negative events on cost-effectiveness in this geriatric population: 1) mild side effects, 2) polypharmacy (use of 5+ medications) associated cognitive impairment, 3) increased risk of falls/fracture, and 4) attenuated effectiveness of therapy in frail older adults Results: We project that treatment to a systolic blood pressure target of 160 mmHg would result in the prevention of 65,000 cases of incident coronary artery disease, and 54,000 cases of incident ischemic stroke in adults 74-95 years. Based on a systolic blood pressure target of 140 mmHg, 191,000 cases of incident coronary artery disease, and 141,000 cases of incident ischemic stroke would be avoided. This would result in 729,000 additional years of life and 992,000 quality-adjusted life years (QALYs). The total health care costs of treating 75-94 year olds to a systolic blood pressure target of 140 mmHg would be $40.5 billion in the U.S., and the cost per QALY would be $40,800. The cost-effectiveness of treatment to a target of 140 mmHg would be worse in the presence of side effects ($ 51,000/QALY), polypharmacy ($ 58,400), fractures ($ 48,400), or frailty ($134,300). Conclusions: Treatment of systolic blood pressure to a target of 140 mmHg would prevent the most cardiovascular events and result in the greatest QALYs gained. The presence of side effects, polypharmacy-related cognitive impairment, fractures, or frailty could substantially offset this benefit. Treatment strategies that are tailored to the health status of older adults are warranted.

The Cost-Effectiveness of Screening the U.S. Blood Supply for West Nile Virus

2005 ◽  
Vol 143 (7) ◽  
pp. 486 ◽  
Author(s):  
Brian Custer ◽  
Michael P. Busch ◽  
Anthony A. Marfin ◽  
Lyle R. Petersen
Keyword(s):  
Cost Effectiveness ◽  
West Nile Virus ◽  
Blood Supply ◽  
West Nile ◽  
The Cost ◽  
The U.S

Modeling the Cost Effectiveness of Child Care Policy Changes in the U.S.

2015 ◽  
Vol 49 (1) ◽  
pp. 135-147 ◽  
Author(s):  
Davene R. Wright ◽  
Erica L. Kenney ◽  
Catherine M. Giles ◽  
Michael W. Long ◽  
Zachary J. Ward ◽  
...  
Keyword(s):  
Child Care ◽  
Cost Effectiveness ◽  
Child Care Policy ◽  
Policy Changes ◽  
Care Policy ◽  
The Cost ◽  
The U.S
Sign in / Sign up

Export Citation Format

Share Document